Rare, Damaging DNA Variants in CORIN and Risk of Coronary Artery Disease: Insights From Functional Genomics and Large-Scale Sequencing Analyses.

Autor: Wang M; Program in Medical and Population Genetics (M.W., J.E.H., P.N., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA.; Cardiovascular Disease Initiative (M.W., V.S.L.-K., D.S.A., N.H.E., J.Y., C.W.G., B.T.M., P.N., V.K.K., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Genomic Medicine (M.W., P.N., S.K., A.V.K.), Massachusetts General Hospital, Boston., Lee-Kim VS; Cardiovascular Disease Initiative (M.W., V.S.L.-K., D.S.A., N.H.E., J.Y., C.W.G., B.T.M., P.N., V.K.K., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA.; Divisions of Genetics and Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (V.S.L.-K., D.S.A.)., Atri DS; Cardiovascular Disease Initiative (M.W., V.S.L.-K., D.S.A., N.H.E., J.Y., C.W.G., B.T.M., P.N., V.K.K., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA.; Divisions of Genetics and Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (V.S.L.-K., D.S.A.)., Elowe NH; Cardiovascular Disease Initiative (M.W., V.S.L.-K., D.S.A., N.H.E., J.Y., C.W.G., B.T.M., P.N., V.K.K., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA., Yu J; Cardiovascular Disease Initiative (M.W., V.S.L.-K., D.S.A., N.H.E., J.Y., C.W.G., B.T.M., P.N., V.K.K., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA., Garvie CW; Cardiovascular Disease Initiative (M.W., V.S.L.-K., D.S.A., N.H.E., J.Y., C.W.G., B.T.M., P.N., V.K.K., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA., Won HH; Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center, Seoul, Gyeonggi, South Korea (H.-H.W.)., Hadaya JE; Program in Medical and Population Genetics (M.W., J.E.H., P.N., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA., MacDonald BT; Cardiovascular Disease Initiative (M.W., V.S.L.-K., D.S.A., N.H.E., J.Y., C.W.G., B.T.M., P.N., V.K.K., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA., Trindade K; Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.T., D.J.R.)., Melander O; Department of Clinical Sciences, Lund University, Malmö, Skåne, Sweden (O.M.).; Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden (O.M.)., Rader DJ; Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.T., D.J.R.)., Natarajan P; Program in Medical and Population Genetics (M.W., J.E.H., P.N., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA.; Cardiovascular Disease Initiative (M.W., V.S.L.-K., D.S.A., N.H.E., J.Y., C.W.G., B.T.M., P.N., V.K.K., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Genomic Medicine (M.W., P.N., S.K., A.V.K.), Massachusetts General Hospital, Boston.; Division of Cardiology (P.N., S.K., A.V.K.), Massachusetts General Hospital, Boston., Kathiresan S; Center for Genomic Medicine (M.W., P.N., S.K., A.V.K.), Massachusetts General Hospital, Boston.; Division of Cardiology (P.N., S.K., A.V.K.), Massachusetts General Hospital, Boston.; Verve Therapeutics, Cambridge, MA (S.K.)., Kaushik VK; Cardiovascular Disease Initiative (M.W., V.S.L.-K., D.S.A., N.H.E., J.Y., C.W.G., B.T.M., P.N., V.K.K., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA., Khera AV; Program in Medical and Population Genetics (M.W., J.E.H., P.N., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Genomic Medicine (M.W., P.N., S.K., A.V.K.), Massachusetts General Hospital, Boston.; Division of Cardiology (P.N., S.K., A.V.K.), Massachusetts General Hospital, Boston., Gupta RM; Program in Medical and Population Genetics (M.W., J.E.H., P.N., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA.; Cardiovascular Disease Initiative (M.W., V.S.L.-K., D.S.A., N.H.E., J.Y., C.W.G., B.T.M., P.N., V.K.K., A.V.K., R.M.G.), Broad Institute of MIT and Harvard, Cambridge, MA.
Jazyk: angličtina
Zdroj: Circulation. Genomic and precision medicine [Circ Genom Precis Med] 2021 Oct; Vol. 14 (5), pp. e003399. Date of Electronic Publication: 2021 Oct 01.
DOI: 10.1161/CIRCGEN.121.003399
Abstrakt: Background: Corin is a protease expressed in cardiomyocytes that plays a key role in salt handling and intravascular volume homeostasis via activation of natriuretic peptides. It is unknown if Corin loss-of-function (LOF) is causally associated with risk of coronary artery disease (CAD).
Methods: We analyzed all coding CORIN variants in an Italian case-control study of CAD. We functionally tested all 64 rare missense mutations in Western Blot and Mass Spectroscopy assays for proatrial natriuretic peptide cleavage. An expanded rare variant association analysis for Corin LOF mutations was conducted in whole exome sequencing data from 37 799 CAD cases and 212 184 controls.
Results: We observed LOF variants in CORIN in 8 of 1803 (0.4%) CAD cases versus 0 of 1725 controls ( P , 0.007). Of 64 rare missense variants profiled, 21 (33%) demonstrated <30% of wild-type activity and were deemed damaging in the 2 functional assays for Corin activity. In a rare variant association study that aggregated rare LOF and functionally validated damaging missense variants from the Italian study, we observed no association with CAD-21 of 1803 CAD cases versus 12 of 1725 controls with adjusted odds ratio of 1.61 ([95% CI, 0.79-3.29]; P =0.17). In the expanded sequencing dataset, there was no relationship between rare LOF variants with CAD was also observed (odds ratio, 1.15 [95% CI, 0.89-1.49]; P =0.30). Consistent with the genetic analysis, we observed no relationship between circulating Corin concentrations with incident CAD events among 4744 participants of a prospective cohort study-sex-stratified hazard ratio per SD increment of 0.96 ([95% CI, 0.87-1.07], P =0.48).
Conclusions: Functional testing of missense mutations improved the accuracy of rare variant association analysis. Despite compelling pathophysiology and a preliminary observation suggesting association, we observed no relationship between rare damaging variants in CORIN or circulating Corin concentrations with risk of CAD.
Databáze: MEDLINE